Company Overview

Arecor is a globally focused biopharmaceutical company that is targeting improving patient care by bringing innovative medicines to market through the enhancement of existing therapeutic products. By applying the Group’s innovative proprietary formulation technology platform, Arestat™, the Group is developing an internal portfolio of proprietary products, as well as working with pharmaceutical and biotechnology companies to deliver enhanced reformulations of their partners’ therapeutic products, supported by an extensive patent portfolio.

The Group is a revenue-generating commercially-focused business with the potential to derive future revenue from multiple existing and future partnering opportunities. The Group’s strategy is to develop an internal portfolio of enhanced proprietary products to a defined value inflexion point prior to partnering with major pharmaceutical and biotechnology companies under a revenue-generating licence model with the potential for the Group to receive royalties and milestone payments. The Group also operates under a technology licensing arrangement when developing enhanced reformulations of its partners’ products, with the potential for milestone and royalty payments.

The Group’s current focus of internal proprietary product development can be divided into two product classes: diabetes and specialty hospital care. In addition, the Group also develops novel enhanced formulations of its partners’ biological products that include biosimilars, biological products and vaccines, which are derived from the Group’s formulation development and technology licensing programmes and are referred to as “Technology Partnerships”.

Arecor Preliminary Results Presentation

25 April 2022

Latest documents

Proactive Investors interview – Arecor Therapeutics’ scientist hopeful that artificial pancreas “edging closer”

15 November 2022

TRINITY DELTA – SPECIALTY HOSPITAL PRODUCTS FORMULATION COLLABORATION

10 November 2022

Proactive Investors interview – Arecor’s study shows rapid-acting insulin could enable artificial pancreas system

12 October 2022

Contact: ir@arecor.com